Danish Cancer Care Transformation: A Model for the UK?

“It was really bad – we had patients dying on the waiting lists – politicians were getting desperate.”

Looking back 25 years, Jesper Fisker, the CEO of the Danish Cancer Society, recalls the dire state of Denmark’s cancer treatment system. During that time, the country struggled significantly with cancer care.

“It was a disaster,” he reflects. “People were even traveling to China to pay for treatments, risking their health in the process.” Many opted for private hospitals in Germany, seeking new treatments not available in Denmark.

At that moment, Denmark’s cancer survival rates lagged behind other wealthy nations. The situation was quite similar in the UK. From 1995 to 1999, Denmark’s five-year survival rate for rectal cancer hovered around 48%, comparable to the UK’s. Both countries fell short of nations like Australia, which boasted a 59% rate.

Fast forward to 2014, and Denmark’s commitment to reforming its approach paid off. The five-year survival rate for rectal cancer surged to 69%, nearing Australia’s statistic (the UK improved too, but only to 62%).

Experts suggest this upward trend has continued, although data is less clear for other cancers. The Danish success has not gone unnoticed by UK officials. Health Secretary Wes Streeting mentioned that elements of the Danish system could influence a new long-term cancer strategy set to be unveiled in England this fall.

Big Investments and Thoughtful Touches

Walking into Herlev Hospital on the outskirts of Copenhagen feels quite different from entering a typical NHS facility. The entrance is adorned with vibrant artwork from Danish artist Poul Gernes, part of an initiative to make the hospital less intimidating and more welcoming.

This focus on atmosphere highlights Denmark’s dedication to enhancing patient experiences alongside funding traditional medical equipment. For instance, Dr. Michael Andersen, a radiologist at the hospital, showcases an advanced scanner, one of only four in use worldwide. Such high-tech tools are integral to Denmark’s cancer treatment strategy.

In 2008, the government committed to investing heavily in scanning equipment, purchasing between 30 and 60 advanced machines—an approach that’s fundamentally transformed their healthcare delivery.

Denmark now boasts around 30 CT scanners per million people, a significant increase compared to the UK’s mere 8.8 scanners per million, based on 2021 data.

Experts assert that this investment has dramatically boosted diagnostic capabilities in Denmark. Without similar funding to meet the rising number of patients in the UK, concerns over quality of care linger.

A Bold Set of Plans

The transformation of Danish healthcare extends beyond equipment. Along with investing in infrastructure, another major shift has seen patients receiving chemotherapy at home. National standards dictate that following a cancer diagnosis, treatment must commence within two weeks. If a hospital fails to adhere to this timeline, patients can transfer to another facility or, if necessary, seek treatment abroad—still covered by the Danish health system.

In contrast, the UK target allows for treatment to start within approximately nine weeks of an urgent cancer referral.

Michelle Mitchell of Cancer Research UK points out a lack of accountability within the English healthcare system, as multiple NHS organizations can create confusion. This, she argues, must be addressed to uplift cancer care quality in the UK.

Going Beyond Just ‘Treating’ Cancer

Elisabeth Ketelsen, an 82-year-old competitive swimmer, exemplifies a patient journey in Denmark. After discovering a breast lump in 2022, she quickly underwent mammography and biopsy, followed by surgery within weeks.

After her cancer returned, Elisabeth was placed on chemotherapy and hormone treatments. Remarkably, she returned to swimming soon after. “The system works,” she asserts.

While most patients experience efficiency, not everyone shares the same praise, though Danish officials claim they meet rapid diagnosis targets for about 80% of patients.

The focus in Denmark seems to extend beyond merely treating cancer; there’s an ongoing effort to improve the overall patient experience. Counseling centers providing therapy and companionship have popped up nationwide, reflecting a comprehensive support system.

Benefits of Chemotherapy at Home

Danish healthcare’s shift toward community-based treatment is further exemplified by recent initiatives allowing patients to receive care at home. Michael Ziegler, who was diagnosed with leukemia, received chemotherapy via a pump in his own living space. “I could engage in activities at home instead of being confined to a hospital room,” he explains, noting the risk of infections in hospitals.

While comprehensive studies on at-home chemotherapy are scarce, some believe that this approach could enhance survival rates by minimizing infection risks during hospital stays.

A Blueprint for the NHS?

The Danish healthcare model shares commonalities with the NHS, notably taxpayer funding. However, the two systems face distinct challenges. For example, England’s population is nearly ten times larger than Denmark’s, and the NHS’s complexity complicates matters further.

Despite these hurdles, UK officials have expressed interest in the Danish healthcare system, evidenced by recent visits to Denmark. Streeting highlighted how Denmark’s approach could enhance NHS services by expediting cancer diagnoses and improving treatment availability.

Experts like Michelle Mitchell posit that Denmark’s methods could serve as a template for the UK. They advocate for more stringent waiting time targets instead of the current, less effective benchmarks.

‘This is Unfinished Business’

However, the NHS also grapples with a myriad of challenges like overcrowded emergency departments and overworked staff. Ruth Thorlby from The Health Foundation points to a historical collective urgency around cancer care shared by both Denmark and the UK in the 1990s. Yet while Denmark followed through, UK initiatives often lost momentum due to shifting priorities.

Ultimately, Denmark’s success can be attributed to a political consensus on the importance of prioritizing cancer care, something that has historically eluded the UK. Fisker emphasizes that long-term partnerships between politicians and health leaders are imperative for sustainable progress.

Turning to the UK’s future, he cautiously suggests that with commitment and investment, substantial improvements can be made—but adds that “nothing comes without investment.”